Medical devices, healthcare technology and the business of care
510(k) clearance · K261409

BioTeke Multi-Drug Urine Test Cup

Bioteke Corporation (Wuxi) Co., Ltd. · Decision date Sep 10, 2026

MEDTECHLEDGER EXPLANATIONK261409

What did the FDA decide?

FDA recorded a substantially equivalent (SESE) decision on 2026-09-10 for K261409, the BioTeke® Multi-Drug Urine Test Cup submitted by Bioteke Corporation (Wuxi) Co., Ltd. The submission was received 04/30/2026 as a traditional 510(k), not reviewed by a third party, and is classified under regulation 862.3100 with primary product code NFT and subsequent codes NFV, NFW, NFY, NGG, NGL, NGM, PTG, PTH and QAW. SESE denotes clearance to market, not PMA approval.

The review document describes the device as a rapid test for qualitative, simultaneous detection of drugs and drug metabolites in human urine. A related CLIA record, CR260360, lists Cannabinoids (THC) as an analyte with moderate complexity and an effective date of 09/30/2026. The source does not state which analytes beyond THC are claimed, cutoff concentrations, or performance results; those details would sit in the FDA review documents rather than the summary fields shown here.

Regulatory pathway
510(k) premarket notification
Clinical specialty
Clinical Toxicology
Decision date
Sep 10, 2026

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
K261409
Regulatory pathway
510(k) premarket notification
Product code
NFT
Decision code
SESE
Decision date
Sep 10, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Test, Amphetamine, Over The Counter.

Product code
NFT
FDA device class
2

FDA decision timeline

  1. K261409 received

    Application receipt date recorded by FDA.

  2. K261409 · FDA decision

    SESE

Related devices and submissions

Explore the linked device profile

No additional submissions with a verified PMA or product-code relationship are linked here.

Regulatory context

A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Bioteke Corporation (Wuxi) Co., Ltd.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
Wuxi

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records